Phase i study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Investigational New Drugs.
Times cited: 21
Basal cell nevus syndrome: A brave new world.
Archives of Dermatology.
Times cited: 17